COVID-19 trials registries data warehouse

 Return to trial list

Trial - ACTRN12622000386730


Column Value
Trial registration number ACTRN12622000386730
Full text link
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Lucas McLindon

Contact
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

info@PACTrial.com.au

Registration date
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2022-03-04

Recruitment status
Last imported at : June 2, 2022, 8 a.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Recruiting

Study design
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Blind label

Center
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

multi-center

Study aim
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

• COVID-19 diagnosis in the preceding 4 days (RAT positive or PCR positive) • At least 40 years old

Exclusion criteria
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

• Women who are pregnant, breastfeeding or actively trying to achieve a pregnancy • Current hospital inpatient with COVID-19 related disease • Allergy to ivermectin, doxycycline or famotidine • Known bleeding disorder • Known severe liver disease • Diagnosis of Myasthenia Gravis/SLE • Consumption of grapefruit juice • Ever travelled to countries that are endemic for Loa loa (West and Central Africa – Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea, Gabon, Republic of Congo, Nigeria and Sudan) • Currently on the following medications: o Cardiac - quinidine, amiodarone, diltiazem, verapamil, warfarin o Anti-infective – clarithromycin, erythromycin, itraconazole, ketoconazole, o Anti-viral – indinavir, ritonavir, cobicistat o Disease modifying – cyclosporine, tacrolimus, sirolimus, methotrexate o Other – retinoids, lithium, spironlactone Neither minority groups nor NESB/LOTE persons will be excluded provided they possess the capacity (ie ability to understand, retain, comprehend and dutifully consider a response) to consent.

Number of arms
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

AProf Dr Karin Ried

Inclusion age min
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

40

Inclusion age max
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

100

Countries
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Australia

Type of patients
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Mild disease at enrollment

Severity scale
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1: Mild disease at enrollment

Total sample size
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

300

primary outcome
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

The primary outcome of this trial is hospital admission.Hospital admission is defined as the requirement to receive inpatient care for a COVID-19 related illness.This can include short stay emergency department admission; hospital in the home (HITH) admission/care; general medical admission; intensive care admission.Assessed by data linkage to patient medical records[daily for 15 days since enrolment]

Notes
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase 1/Phase 2

Arms
Last imported at : March 11, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "", "treatment_id": 2404, "treatment_name": "Doxycycline+famotidine+ivermectin+vitamin c+vitamin d+zinc", "treatment_type": "Antibiotics+others pharmacological treatment+antiparasitics+vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2403, "treatment_name": "Doxycycline+ivermectin+vitamin c+vitamin d+zinc", "treatment_type": "Antibiotics+antiparasitics+vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}]